Navigation Links
NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
Date:9/15/2008

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the three co-primary efficacy endpoints at week-13 (p<0.001). The study also comfortably met the main secondary endpoint, demonstrating that naproxcinod 750 mg bid was statistically non-inferior to naproxen 500 mg bid on the WOMAC(TM) pain and function subscales at week-13 and 26. Naproxcinod is the first compound in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donator (CINOD) class of anti-inflammatory agents, which NicOx is developing as a drug for the treatment of the signs and symptoms of osteoarthritis.

NicOx' phase 3 clinical program for naproxcinod consists of three pivotal trials (including the previously completed 301 study in osteoarthritis of the knee and the ongoing 303 study in osteoarthritis of the hip, in addition to the 302 study). Overall, the results of the 302 study support naproxcinod's non-detrimental effect on blood pressure and are consistent with those observed in the 301 study, with naproxcinod 750 mg bid showing a numerical reduction in systolic and diastolic blood pressure at week-13 and 26, compared to baseline and naproxen 500 mg bid. Existing non-steroidal anti-inflammatory agents (NSAIDs) such as ibuprofen and naproxen have the tendency to raise blood pressure, which is a side effect of particular concern in the osteoarthritis population.

A post hoc pooled analysis of the blood pressure data from the 301 and 302 studies showed a statistically significant reduction for naproxcinod 750 mg bid, compared to naproxen 500 mg bid, in terms of the mean change from baseline at week-13, of 2.3 mmHg (p=0.004) for systolic blood pressure and 1.1 mmHg (p=0.034) for diastolic blood pressure. In the planning of the phase 3 program, NicOx had fo
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
2. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
3. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
4. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
5. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
6. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
9. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
10. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
11. NicOx Naproxcinod ABPM Data Presented at American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... our Medicare resources and continue highlighting the success of the prescription drug benefit, commonly ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Inc. (NYSE: WPI ) today announced that ... with Endo Pharmaceuticals, Inc. on outstanding patent litigation related ... its lawsuit on March 4, 2010, following Watson,s filing ... U.S. Food and Drug Administration (FDA) for seeking approval ...
... Inc. (Nasdaq: AKRX ) will host a conference ... results followed by a Q&A session.  The company will release ... Akorn Third Quarter 2010 Conference CallDate/Time: , Tuesday, November ... (888) 215-6895International Callers: , (913) 312-0860Confirmation Code: , ...
Cached Medicine Technology:Watson Reaches Settlement with Endo Over Opana® ER 2
(Date:7/31/2015)... ... , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest ... this new applicator in the United States as an upgrade to the CoolSmooth applicator ... original applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation ... Conference Center. The medical community, social workers, law enforcement, and government officials are ... in the effort to better understand and combat sex trafficking. Lead by sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that ... and VIPs at the 2015 Vans US Open of Surfing, July 25 through August ... claim “no added sugar” on the market, is a natural choice given the Open’s ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... looking to catch a new and refreshing show on Broadway, look no further than ... including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel Award, ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Should be considered along with LDL cholesterol ... 12 (HealthDay News) -- A new study showing ... of cardiac trouble strengthens the case for including ... , "Triglycerides traditionally have been viewed as second-class ...
... Global Trends, Progress and ... ANNAPOLIS, Md., Feb. 12 iJET Intelligent ... business resiliency services,today announced the publication of 2007 ... by iJET,s health intelligence team, the report,provides analysis ...
... CHICAGO (February 12, 2008) A new study published in ... of Surgeons shows that patients with a large support network ... prior to having a surgical procedure, which can have a ... findings suggest that it is important for clinicians to be ...
... of Frozen Desserts Nationwide Fuels ... Cefiore,s ... and one of the nation,s fastest-growing frozen yogurt,destinations, introduced today its ... 90% of U.S. households consuming frozen,desserts and many choosing frozen yogurt ...
... 12 Natural,Alternatives International, Inc. ("NAI") (Nasdaq: ... customized nutritional,supplements, today announced the appointment of Kenneth ... Mr. Wolf possesses over 20,years of manufacturing and ... as Chief Financial Officer with Phoenix Footwear Group, ...
... AKRON, Ohio, Feb. 12 Planning for the WKDD ... progressing effortlessly,when a company backed out at the last ... listening to the radio at just the right,moment., ... to WKDD, and [on-air personality] Matt Patrick was,discussing a ...
Cached Medicine News:Health News:Triglycerides Linked to Coronary Disease Risk 2Health News:Triglycerides Linked to Coronary Disease Risk 3Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 2Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 3Health News:Patients with larger social networks may fare better after an operation 2Health News:Latest Salvo Fired in Frozen Yogurt Wars as Southern California's Fastest-Growing Franchise - Cefiore - Launches New Chocolate Flavor 2Health News:Natural Alternatives International, Inc. Appoints New Chief Financial Officer 2Health News:Natural Alternatives International, Inc. Appoints New Chief Financial Officer 3Health News:Virtual Hold Technology Donates Toys, Helps Raise Money for WKDD's Annual Radiothon for Akron Children's Hospital 2
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: